Ionis reports $434.1 million of 0.125% convertible notes repurchased

Chicago, June 12 – Ionis Pharmaceuticals Inc. announced that it has repurchased $434.1 million principal amount of its 0.125% convertible senior notes due 2024 in privately negotiated transactions, according to an 8-K filing with the Securities and Exchange Commission.

The company intends to use a new $575 million offering of convertible notes to further repurchase the issue of convertibles.

There were $548.9 million of the convertible notes originally issued.

Ionis Pharmaceuticals is a Carlsbad, Calif.-based biotech company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.